Asia Pacific Sglt2 Inhibitors Market Size & Outlook
Related Markets
Asia Pacific sglt2 inhibitors market highlights
- The Asia Pacific sglt2 inhibitors market generated a revenue of USD 2,230.4 million in 2024.
- The market is expected to grow at a CAGR of 7.2% from 2025 to 2033.
- In terms of segment, jardiance (empagliflozin) was the largest revenue generating drug in 2024.
- Other Drug is the most lucrative drug segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2025 to 2033.
Asia Pacific data book summary
| Market revenue in 2024 | USD 2,230.4 million |
| Market revenue in 2033 | USD 4,154.6 million |
| Growth rate | 7.2% (CAGR from 2025 to 2033) |
| Largest segment | Jardiance (empagliflozin) |
| Fastest growing segment | Other Drug |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Jardiance (Empagliflozin), Farxiga (Dapagliflozin), Invokana (Danagliflozin), Inpefa (Sotagliflozin), Qtern (Dapagliflozin/Saxagliptin), Other Drug |
| Key market players worldwide | Boehringer Ingelheim International GmbH, AstraZeneca PLC, Merck & Co., Inc., Johnson & Johnson Services, Inc., TheracosBio, Lexicon Pharmaceuticals, Eli Lilly and Company, Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Ltd. |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 13.2% of the global sglt2 inhibitors market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 4,154.6 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
SGLT2 Inhibitors Market Scope
SGLT2 Inhibitors Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| TheracosBio | View profile | 1-10 | Framingham, Massachusetts, United States, North America | http://www.theracosbio.com |
| Lexicon Pharmaceuticals | View profile | 101-250 | The Woodlands, Texas, United States, North America | http://www.lexpharma.com |
| Glenmark Pharmaceuticals Ltd. | View profile | - | - | - |
| Boehringer Ingelheim International GmbH | View profile | - | - | - |
| Eli Lilly and Company | View profile | - | - | - |
| Merck & Co., Inc. | View profile | - | - | - |
| Johnson & Johnson Services, Inc. | View profile | - | - | - |
| Bristol-Myers Squibb Company | View profile | - | - | - |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
Asia Pacific sglt2 inhibitors market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to sglt2 inhibitors market will help companies and investors design strategic landscapes.
Jardiance (empagliflozin) was the largest segment with a revenue share of 61.55% in 2024. Horizon Databook has segmented the Asia Pacific sglt2 inhibitors market based on jardiance (empagliflozin), farxiga (dapagliflozin), invokana (danagliflozin), inpefa (sotagliflozin), qtern (dapagliflozin/saxagliptin), other drug covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to Asia Pacific sglt2 inhibitors market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific sglt2 inhibitors market databook
-
Our clientele includes a mix of sglt2 inhibitors market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific sglt2 inhibitors market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific sglt2 inhibitors market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific sglt2 inhibitors market size, by country, 2021-2033 (US$M)
Asia Pacific SGLT2 Inhibitors Market Outlook Share, 2024 & 2033 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
